BEIJING (Reuters) - Wang Xing, CEO of China's largest food delivery firm Meituan, said on Friday in a post-earnings call that ...
The drugmaker plans to build a research-and-development center in Beijing and strike deals with local biotechnology companies ...
Beijing’s threat to stop a tycoon’s sale of his ports business has dealmakers wondering if they can still operate without ...
LONDON (Reuters) - AstraZeneca said on Friday it will spend $2.5 billion on a research and development hub in Beijing, as the ...
The China Civil Engineering Construction Corporation (CCECC) will invest $1.4 billion to upgrade the Tanzania-Zambia railway, ...
British pharmaceutical giant AstraZeneca announced on Friday that it will invest $2.5 billion in a research and development ...
Property investment in China fell 9.8% in the first two months of 2025 from the same period a year earlier, after tumbling 10 ...
BEIJING -- China will work to further stabilize foreign investment in 2025, implementing measures to open up more fields and ...
AstraZeneca (AZN) stock in focus as the company invests $2.5B in Beijing for a new R&D center, strengthening its footprint in ...
SHANGHAI -- Executives at China's Ping An Insurance on Thursday struck an optimistic tone over the country's stock market, ...
Tax revenues have fallen, leaving the government with less money to help consumers or exporters as Beijing braces for ...
Trading volumes of iShares China Large-Cap ETF, which tracks Chinese blue-chip stocks, swelled 2.8 times in February, according to data from global investing platform Vested Finance. In this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results